National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.

abstract：:Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kharod BV,Carlson AN

更新日期：2007-04-01 00:00:00

abstract：INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vergnenègre A,Chouaïd C

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gimeno-Ballester V,Mar J,San Miguel R

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vogler S,Zimmermann N,Babar ZU

更新日期：2017-04-01 00:00:00

abstract：:Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： De Franco AC,Oldridge N

更新日期：2014-02-01 00:00:00

abstract：OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kawalec P,Malinowski KP,Trąbka W

更新日期：2018-04-01 00:00:00

abstract：:Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

更新日期：2013-04-01 00:00:00

abstract：:The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

更新日期：2017-04-01 00:00:00

abstract：:Healthcare reform in any nation is an evolving process. Brought about by demographic, technological, social, cultural, economic and political factors, all healthcare systems are continually confronting issues related to cost, access and quality. This paper examines other countries' approaches to healthcare in the ongo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： O'Rourke TW,Iammarino NK

更新日期：2002-06-01 00:00:00

abstract：AIM:To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS:This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Roger A,Fortea J,Mora S,Artés M

更新日期：2008-08-01 00:00:00

abstract：INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Drost RM,Paulus AT,Ruwaard D,Evers SM

更新日期：2017-02-01 00:00:00

abstract：:Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lim MK

更新日期：2006-12-01 00:00:00

abstract：:This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cummins RA,Lau AL,Stokes M

更新日期：2004-08-01 00:00:00

abstract：:Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Menon D,Stafinski T

更新日期：2011-02-01 00:00:00

abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. METHODS:A cross sectional study was carried out (2011-14) in the Department of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kamat N,Pai G,Mallayasamy SR,Kamath A,S R

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

更新日期：2017-08-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuipers P,Foster MM,Bellamy N

更新日期：2003-04-01 00:00:00

abstract：:Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hindelang M,Kirsch F,Leidl R

更新日期：2020-02-01 00:00:00

abstract：:In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grant WC,Yoder DM,Mullins CD

更新日期：2004-04-01 00:00:00

abstract：:Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Baker DA

更新日期：2005-12-01 00:00:00

abstract：OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

更新日期：2020-07-20 00:00:00

abstract：:In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Snyder C,Gotay CC,Lipscomb J

更新日期：2006-08-01 00:00:00

abstract：INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2019-04-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

更新日期：2018-04-01 00:00:00

abstract：:Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2003-06-01 00:00:00